Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

87.04CHF
4:30pm BST
Change (% chg)

CHF1.16 (+1.35%)
Prev Close
CHF85.88
Open
CHF86.00
Day's High
CHF87.28
Day's Low
CHF85.66
Volume
6,238,623
Avg. Vol
4,458,376
52-wk High
CHF88.30
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 30.91 33.65
EPS (TTM): 2.68 -- --
ROI: 6.14 14.75 14.28
ROE: 9.19 16.25 16.00

BRIEF-Novartis - Lutathera® Data Shows Significant PFS Improvement

* ANNOUNCES PRESENTATION OF NEW LUTATHERA® NETTER-1 DATA AT ESMO DEMONSTRATING SIGNIFICANT IMPROVEMENT IN PFS REGARDLESS OF BASELINE LIVER TUMOR BURDEN

6:27am BST

FDA snubs Novartis bid to repurpose inflammation drug for heart attacks

ZURICH The U.S. Food and Drug Administration has rejected Novartis's bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, the Swiss drugmaker said on Thursday.

18 Oct 2018

FDA snubs Novartis bid to repurpose inflammation drug for heart attacks

ZURICH, Oct 18 The U.S. Food and Drug Administration has rejected Novartis's bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, the Swiss drugmaker said on Thursday.

18 Oct 2018

BRIEF-Endocyte - To pay Novartis AG $73.5 mln deal termination fee under certain conditions

* ENDOCYTE SAYS CO WILL BE OBLIGATED TO PAY NOVARTIS AG TERMINATION FEE OF $73.5 MILLION, IF DEAL IS TERMINATED UNDER CERTAIN CONDITIONS- SEC FILING

18 Oct 2018

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion (£1.6 billion) for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

18 Oct 2018

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

18 Oct 2018

UPDATE 2-Novartis pushes deeper into nuclear medicine with $2.1 bln deal

* Analysts say Q3 results take back seat to deal (Adds comments from CEO, shares, details throughout)

18 Oct 2018

Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

18 Oct 2018

UPDATE 1-Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash

Oct 18 Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

18 Oct 2018

Swiss stocks - Factors to watch on Oct. 18

ZURICH/BERLIN, Oct 18 The Swiss blue-chip SMI was seen opening 0.1 percent higher at 8,760 points on Thursday, according to premarket indications by bank Julius Baer .

18 Oct 2018

Earnings vs. Estimates